Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
Morning Overview on MSN
A nasal spray reversed signs of brain aging in early tests, and a patent is already filed
Researchers at Texas A&M University reported that two intranasal doses of extracellular vesicles derived from human neural ...
The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its ...
Newron Pharmaceuticals provides update following Type A meeting with the US FDA: Milan, Italy Saturday, July 4, 2026, 10:00 Hrs [IST] Newron Pharmaceuticals S.p.A. (Newron), a bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results